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Ligand-induced Conformational Alterations of the Androgen
Receptor Analyzed by Limited Trypsinization
STUDIES ON THE MECHANISM OF ANTIANDROGEN ACTION*
(Received for publication, April 17, 1995, and in revised form, June 23, 1995)
Cor W. Kuil‡, Cor A. Berrevoets, and Eppo Mulder
From the Department of Endocrinology and Reproduction, Erasmus University Rotterdam, P. O. Box 1738,
3000 DR Rotterdam, The Netherlands
Limited proteolysis of in vitro produced human andro-
gen receptor was used to probe the different conforma-
tions of the receptor after binding of androgens and
several antiandrogens. The results provide evidence for
five different conformations of the receptor, as detected
by the formation of proteolysis resisting fragments: 1)
an initial conformation of the unoccupied receptor not
resisting proteolytic attack; and receptor conformations
characterized by 2) a 35-kDa proteolysis resisting frag-
ment spanning the ligand binding domain and part of
the hinge region, obtained with most antagonists, and in
an initial step after agonist binding; 3) a 29-kDa prote-
olysis resisting fragment spanning the ligand binding
domain, obtained in the presence of agonists after an
activation process; 4 and 5) 30- and 25-kDa fragments,
derived from 2 and 3, but missing part of the C terminus,
obtained with RU486 (RU486 has antiandrogenic prop-
erties, besides its effects as an antiprogestagen/antiglu-
cocorticoid). Concomitantly with the change from 2 to 3
(and of 4 to 5 for RU486), dissociation of the 8 S complex
of receptor with associated proteins occurred. With a
mutant receptor (LNCaP cell mutation in C-terminal
region), some antagonists activated transcription anal-
ogous to agonists, and induced the activated receptor
conformation 3. A mutant lacking the C-terminal 12
amino acids bound RU486 but not androgens, and
formed with RU486 conformation 5. These data imply
that, after the initial rapid binding of ligand, androgens
induce a conformational change of the receptor, a proc-
ess that also involves release of associated proteins.
RU486 induces an inappropriate conformation of the
C-terminal end, similar as found for its effect on the
progesterone receptor. In contrast, the other antiandro-
gens act at a different step in the mechanism of action:
they do not induce an abnormal conformation, but act
earlier and prevent a conformation change by stabiliz-
ing a complex with associated proteins.
The biological effects of androgens and other steroid hor-
mones are mediated through intracellular receptors, belonging
to the steroid and thyroid hormone receptor superfamily (1).
Upon activation by the hormone, steroid receptors interact
with specific DNA sequences, located in the flanking regions of
target genes, resulting in modulation of the expression of these
genes (2–4). Steroid hormone receptor antagonists inhibit the
biological effects of agonists, and are frequently used in the
treatment of hormone-based dysfunctions in human. Further-
more, the synthetic antagonists are important tools to define
the molecular mechanism of transactivation by steroid
hormones (5, 6).
Agonists and antagonists may change the spatial structure
of the receptor in distinct ways, as was first indicated by gel
retardation experiments: antagonist- and agonist-receptor-
DNA complexes showed slightly different mobilities (7–10).
Recently, limited proteolysis of progesterone, estrogen, and
glucocorticoid receptors pinpointed the distinction in conforma-
tion between hormone- and antihormone-bound receptor at the
very C-terminal end of the receptor. Hormone treatment in-
duced a pronounced conformational change in receptor struc-
ture, resulting in a prominent proteolysis resisting fragment.
Several antagonists, including those which inhibit binding of
the receptor to a hormone responsive element in vitro, induced
an equally dramatic but distinct change in the receptor confor-
mation; the proteolysis resisting fragments induced by binding
of the different antagonists to their receptors were smaller
than that induced by hormone binding (11–13). In addition, the
monoclonal antibody C-262, raised against the last 14 amino
acids of the progesterone receptor, could discriminate agonist-
and antagonist-bound progesterone receptors. The antibody
bound to the full-length receptor only in the presence of antag-
onist, whereas progesterone prevented the recognition of the
receptor by C-262 (14, 15). Deletion of 42 amino acids abolished
the binding of progesterone, but had no effect on binding of the
antagonist RU486. Functional characterization showed that
the mutant receptor induced transcription upon addition of
RU486 (14). These results led to the hypothesis that the activ-
ity of antagonists is based on the induction of a non-functional
conformation at the C terminus of steroid hormone receptors
(4–6, 11).
Androgen binding to the androgen receptor (AR)1 changed
the receptor structure in such a way that the entire ligand
binding domain resisted proteolytic degradation (10, 16, 17).
However, for the antiandrogen-bound receptor, the outcome of
preliminary studies on resistance against proteolytic degrada-
tion varied in different investigations. An unaltered conforma-
tion of the ligand binding domain, similar as seen in the ab-
sence of ligand, was reported by Kallio et al. (10). A structural
difference between agonist- and antagonist-receptor complexes
in the area around the hinge region of the receptor was deduced
from studies in our laboratory. In the presence of an antian-
drogen, a part of the hinge region in addition to the ligand
* The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
“advertisement” in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
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1 The abbreviations used are: AR, wild-type human androgen recep-
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binding domain resisted proteolysis (16). Finally, Zeng et al.
(17) observed no difference in the size of the proteolysis resist-
ing fragments in the presence of either the agonist dihydrotes-
tosterone or the antagonists cyproterone acetate and hydroxy-
flutamide. Despite these differences in results, none of these
three studies provided evidence for the involvement of the C
terminus of the androgen receptor in the mechanism of anti-
androgen action. Therefore, the differences in structural alter-
ation of the homologous ligand binding domains of steroid
hormone receptors by antiandrogens and by other steroid re-
ceptor antagonists may reflect a difference in the mechanisms
of antagonist action.
In this paper we extend the studies on androgen receptor
conformation by inclusion of conditions that affect the trans-
formation process of receptors. In addition, RU486 was in-
cluded. Due to its broad steroid specificity, this compound also
binds to the androgen receptor, although with a much lower
affinity than for the progesterone and glucocorticoid receptor
(18, 19). Furthermore, we used the mutant receptor ARL
(LNCaP mutant)(20) to assess a correlation between the
ligand-induced conformational alteration of the receptor and
the ability to activate transcription in transfection studies. The
results indicate a similarity in conformational alterations for
the different steroid hormone receptors, but a distinction in
mechanism of action between most antiandrogens and antag-
onists for other steroid hormone receptors.
EXPERIMENTAL PROCEDURES
Materials—[3H]R1881 (87 Ci/mmol) and unlabeled R1881 (methyl-
trienolone) were purchased from DuPont NEN. [3H]RU486 (38.4 Ci/
mmol), unlabeled RU486 (RU 38486, mifepristone), and nilutamide (RU
23908) were gifts from Roussel Uclaf (Romainville, France); cyproterone
acetate was from Schering AG (Berlin, Germany); hydroxyflutamide
from Schering (Bloomfield, IL); and ICI 176.334 (“Casodex”) from ICI
Pharmaceuticals (Macclesfield, United Kingdom). L-[35S]Methionine
(.1000 mCi/mM) was obtained from Amersham (Buckinghamshire,
UK); RNA transcription kit and pBluescript KS2 from Stratagene;
rabbit reticulocyte lysate and recombinant RNasin from Promega; tryp-
sin (type III), goat anti-mouse agarose, and goat anti-rabbit agarose
from Sigma; and BM chemiluminescence Western blotting kit from
Boehringer Mannheim (Mannheim, Germany). The mouse monoclonal
antibody AC88 (recognizing HSP90) was generously provided by Dr. D.
O. Toft (Mayo Clinic, Rochester, MN).
Plasmid Construction—The expression vectors pSVAR (encoding a
human AR of 910 amino acids) (21) and pSVARL (LNCaP mutation;
codon 868, Thr to Ala of an AR of 910 amino acids) (20) were used for
subcloning in pBluescript to obtain pBSAR and pBSARL, respectively
(16). The plasmid pBSAR 1–898, encoding a receptor with a C-terminal
deletion of 12 amino acids, was constructed from pSVAR 1–898 (22).
The mouse mammary tumor virus-luciferase (MMTV-LUC) reporter
plasmid was kindly provided by Organon (Oss, The Netherlands).
Cell Culture and Transfection—HeLa cells were cultured and trans-
fected, with some modifications, as described previously (23). For tran-
scription regulation studies, 1.5 3 105 HeLa cells/well (10 cm2) were
transfected with either 0.5 mg of pSVAR or 0.5 mg of pSVARL, and 0.5
mg of MMTV-LUC, per well. Carrier DNA (pTZ) was added to a total of
5 mg/well. After 1 day, a glycerol shock (15% (w/v) glycerol in serum-free
minimal essential medium, 1.5 min) was performed, whereafter the
cells were washed and experimental media were added. Two days after
transfection, cells were harvested for the luciferase assay.
Luciferase Assay—For the luciferase (LUC) assay, 200 ml of lysis
buffer (25 mM Tris phosphate (pH 7.8), 15% glycerol, 1% Triton X-100,
8 mM MgCl2, 1 mM dithiothreitol) was added to the phosphate-buffered
saline-washed cells. After an incubation for 10 min, supernatants were
collected, 100 ml of luciferine solution (1 mM luciferine, 1 mM ATP in
lysis buffer) added, and luciferase activity was measured with a LU-
MAC Biocounter M2500. In the absence of hormone, LUC activity was
less then 10% of the highest levels of LUC activity (at 1029-1028 nM
R1881). Experiments were performed in triplicate.
In Vitro Transcription and Translation—Both in vitro transcription
and translation, in the presence of unlabeled or [35S]methionine, were
performed according to the manufacturer’s instruction. Sense mRNA
produced from pBSAR, pBSARL, and pBSAR 1–898 was used for
translation.
Limited Trypsinization Assay—Two ml of labeled translation mixture
was incubated at 25 °C with 3 ml of ligand solution diluted in water for
the indicated time. Limited trypsinization was performed by addition of
5 ml of trypsin solution (dissolved in water) either at 25 °C (15 min; 40
mg/ml trypsin) or at 0 °C (1 h; 100 mg/ml trypsin). After incubation, 20
ml of 1.5 3 SDS sample buffer was added. Samples were electrophore-
sed (24) and autoradiography was performed overnight. In some exper-
iments, immunoadsorbed receptor protein was used. Of the resus-
pended resin with adsorbed receptor protein, 80 ml was incubated with
10 ml of ligand solution for 1 h at 25 °C, whereafter 10 ml of trypsin
solution (50 mg/ml) was added to the incubation mixture. After this
incubation 25 ml of 5 3 SDS sample buffer was added, samples were
boiled, the resin removed by centrifugation, and 25 ml was loaded on the
gel.
Immunoprecipitation of Receptor Fragments and Intact Receptor—
Soybean trypsin inhibitor was added to the digestion mixture to a final
concentration of 200 mg/ml. Goat anti-rabbit or goat anti-mouse agarose
(100 ml, diluted 1:4 in phosphate-buffered saline) was incubated for 2 h
at 4 °C with 1 ml of polyclonal rabbit antiserum SP066 (epitope amino
acids 892–910) (25) or mouse monoclonal antiserum F52 (epitope amino
acids 593–612) (26). Following this incubation, the resin was washed
with phosphate-buffered saline and added to the limited proteolytic
digest of the receptor. After incubation for 2 h at 4 °C, the resin was
washed with phosphate-buffered saline, and 25 ml of sample buffer was
added. Electrophoresis was performed as described above (24).
Immunoadsorbed intact receptor was prepared with polyclonal rab-
bit antiserum SP197 (epitope amino acids 1–20)(27) from a non-di-
gested translation mixture. After incubation for 2 h at 4 °C, the resin
was washed with 0.5 M NaCl in buffer A (40 mM Tris/HCl (pH 7.4), 10
mM EDTA, 10% (w/v) glycerol), and resuspended in 1 ml of buffer A,
containing 1 mg/ml bovine serum albumin, for proteolytic digestion
experiments.
Western Immunoblot Analysis—Imunoaffinity purification andWest-
ern immunoblot analysis of androgen receptor complexes from LNCaP
cells was performed as described previously (23). In short, the mono-
clonal antibody F39.4.1, specific for the androgen receptor (25), was
chemically cross-linked to protein A-Sepharose and incubated with
cytosol for 2 h at 4 °C under rotation. Subsequently, the resin was
washed in buffer A with or without 0.5 M NaCl, whereafter electro-
phoresis and Western blotting was performed. The monoclonal antibod-
ies AC88, specific for HSP90 (28), and F39.4.1 were used as primary
antibodies in a chemiluminescence protein detection method, per-
formed as described by the manufacturer (Boehringer Mannheim).
Sucrose Density Gradients—Sucrose density gradients (5–20% (w/v)
sucrose) were prepared in buffer B (40 mM Tris/HCl (pH 7.4), 10% (w/v)
glycerol, 10 mM dithiothreitol, 10 mM Na2MoO4, 50 mM NaCl). In ex-
periments with labeled ligands, reticulocyte lysate containing unla-
beled translation products (25 ml) was incubated with either 10 nM
[3H]R1881 or 100 nM [3H]RU486 to label the receptor. For determina-
tion of nonspecific binding, 100-fold unlabeled steroid was added. La-
beling occurred either for 2 h at 4 °C or 1 h at 25 °C, before addition of
25 ml of buffer B. Thereafter, free steroid was removed by incubation
with 25 ml of dextran-coated charcoal suspension (0.1% (w/v) dextran,
1% (w/v) charcoal in 40 mM Tris/HCl (pH 7.4)) and centrifugation.
Samples of 65 ml were loaded onto the gradients and run for 2 h at
60,000 rpm in a VTi 65 rotor (Beckman) at 4 °C. Fractions were col-
lected from the bottom and assayed for radioactivity. Hemoglobin (4.6
S), alkaline phosphatase (6.2 S), and 14C-labeled aldolase (7.9 S) were
used as markers.
When no labeled ligand (antiandrogens) was available, [35S]methi-
onine was used to label translation products, and incubation occurred in
the presence of unlabeled ligands. After sucrose density gradient cen-
trifugation, fractions were denatured and electrophoresed as described
under limited trypsinization assay. Autoradiograms were scanned, and
density was calculated from recorded data.
Hormone Binding Assay—The hormone binding assays were per-
formed with reticulocyte lysate containing unlabeled translation prod-
ucts. Lysate (10 ml) was incubated overnight at 4 °C with increasing
concentrations of [3H]RU486 (0.3–100 nM). In parallel incubations, 100-
fold unlabeled RU486 was included to assess nonspecific binding. Sep-
aration of bound and free steroid was done with protamine precipitation
as described previously (20). Scatchard plot analysis was performed to
determine binding constants.
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RESULTS
Transcription Activation—To compare the antiandrogenic
properties of several antiandrogens, transcription activation
was studied in a transient transfection system with either the
wild-type AR or a mutant androgen receptor (ARL). The AR
and ARL expression vectors were transfected into HeLa cells,
together with the androgen receptor-sensitive reporter plasmid
MMTV-LUC. The non-metabolizable, synthetic androgen
R1881 induced LUC activity in a dose-dependent manner (Fig.
1). Cyproterone acetate and RU486 showed a limited partial
agonistic effect with AR at concentrations up to 100 nM,
whereas partial agonistic activity was not observed for hy-
droxyflutamide and ICI 176.334. In contrast, in cells with the
mutant receptor ARL, cyproterone acetate and hydroxyflut-
amide induced LUC activity to the same levels as that observed
with R1881. A partial agonistic activity of RU486 on ARL was
found, whereas ICI 176.334 did not activate ARL. HeLa cells
contain a limited amount of glucocorticoid receptor and RU486
is able to bind to these receptors. However, effects of RU486 on
transcription activation were not due to this receptor system;
in the absence of AR or ARL expression vectors, RU486 failed
to induce LUC activity from the transfected MMTV-LUC re-
porter plasmid (not shown). Thus, with respect to its antian-
drogenic properties, RU486 acted as an antagonist in the tran-
sient transfection system with AR and ARL, and did not show
a higher agonistic activity for ARL than for AR.
Protease Resistance of Androgen- and Antiandrogen-Receptor
Complexes—For study of the ligand-induced conformational
changes of the AR, in vitro produced AR was incubated in the
presence of ligand for different periods of time at 25 °C, where-
after limited trypsinization was performed at 0 °C and prote-
olysis resisting fragments were analyzed (Fig. 2A). When both
the androgens R1881 (10 nM), testosterone (100 nM), or dihy-
drotestosterone (10 nM) and the trypsin were added simulta-
neously (i.e. no preincubation of receptor and steroid at 25 °C),
a 35-kDa proteolysis resisting fragment of the AR was formed
(result shown for R1881: Fig. 2A, lane 4). In the absence of
ligand the receptor is completely degraded (Fig. 2A, lane 2).
Addition of hormone therefore immediately induces a change in
the conformation of the AR in such a way that the receptor was
no longer completely degraded. With increasing incubation
times at 25 °C, a shift in abundance of the 35-kDa proteolysis
resisting fragment to a 29-kDa proteolysis resisting fragment
of the AR occurred (Fig. 2A, lanes 4–7). This shift in size of the
proteolysis resisting fragment indicates a second conforma-
tional change of the AR induced by androgens. The antiandro-
gens hydroxyflutamide (10 mM), cyproterone acetate (1 mM), ICI
176.334 (10 mM), and RU 23908 (1 mM) also immediately in-
duced resistance of a 35-kDa fragment of AR against
trypsinization, but no conformational alteration was observed
within an incubation period of 60 min at 25 °C (result shown for
hydroxyflutamide: Fig. 2A, lanes 8–11). In contrast to these
antiandrogens, the presence of RU486 (1 mM) resulted in for-
mation of 35- and 30-kDa proteolysis resisting fragments of the
AR, and in a time-dependent shift toward shorter 29- and
25-kDa fragments (Fig. 2A, lanes 12–15). Next, antisera were
used to study the differences in composition of the proteolysis
resisting fragments of the AR, incubated for 60 min at 25 °C
before trypsinization. The C terminus of the ligand binding
domain of the RU486-bound AR did not resist trypsinization, as
the 25-kDa fragment could not be immunoprecipitated with the
antiserum SP066 (epitope at C terminus). In contrast, both the
35- and 29-kDa fragments could be precipitated with this an-
tiserum (Fig. 2B, lanes 16–21). Because both these last two
fragments contain the C terminus of the ligand binding do-
main, the differences in size are due to differences in extension
into the hinge region, a region located at approximately 250
amino acids from the C terminus. The antiserum F52 recog-
nizes an epitope in the DNA binding domain, adjacent to the
hinge region. None of the proteolysis resisting fragments could
FIG. 1. Transcriptional activity of the AR and LNCaP andro-
gen receptor (ARL) in the presence of androgen, antiandrogens,
and RU486. LUC activity was determined in HeLa cells co-transfected
with pSVAR or pSVARL andMMTV-LUC. After transfection, cells were
incubated with R1881, hydroxyflutamide (OH-F), cyproterone acetate
(CA), ICI 176.334 (ICI334) or RU486. LUC activity is indicated as
percentage of the activity induced by 0.1 nM R1881 (5100%). LUC
activities, induced by the indicated ligands are represented by closed
bars. Open bars represent competition of 0.1 nM R1881 with the other
ligands. The mean values of at least two experiments are shown. A LUC
activity of ,5% of that induced by 0.1 nM R1881 was observed with 10
nM R1881 in the absence of pSVAR or pSVARL, or in the absence of
hormone.
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be immunoprecipitated with the antiserum F52 (not shown),
indicating the absence of the DNA binding domain in all
fragments.
In conclusion, these results show differences in interaction
with the receptor between antiandrogens cyproterone acetate,
hydroxyflutamide, ICI 176.334, and RU 23908 and the antian-
drogen RU486. Furthermore, they emphasize that receptors
complexed with antiandrogens (except RU486) do not contain a
trypsin-sensitive site available for the cleavage of the C-termi-
nal 30–40 amino acids.
Effect of Molybdate and Immunoadsorption on Proteolysis
Resisting Conformation—Transformation by hormones of ste-
roid hormone receptor complexes into an activated form is
thought to be accompanied by the release of several associated
proteins, mainly belonging to the family of heat shock proteins
(HSPs; reviewed in Refs. 29 and 30). A 90-kDa heat shock
protein (HSP90) is the major component in this complex and
has been shown unambiquously to be part of unactivated ste-
roid receptor complexes, both in vivo and in vitro. The HSPs are
predominantly bound to the ligand binding domain of steroid
receptors. Release of the HSPs may be involved in the time-de-
pendent conformational changes in the ligand binding domain
that are detected with the limited trypsinization procedure in
androgen- and RU486-bound receptors. Molybdate is known to
stabilize steroid receptor-HSP interactions (29). It was ob-
served, that the time-dependent conformational change of AR
induced by androgens and by RU486 was also delayed by the
addition of molybdate (Fig. 3A). With antiandrogens, addition
of molybdate increased the amount of the 35-kDa proteolysis
resisting fragment (Fig. 3A, lanes 6 and 7). In the absence of
ligand (Fig. 3A, lanes 2 and 3), addition of molybdate had no
effect; protected fragments were still not detectable. These
results indicate that molybdate stabilized the first proteolysis
resisting conformation of the receptor that is initially formed
after binding of the ligand, and suggest a role for associated
(heat-shock) proteins in the process of time-dependent confor-
mation change.
The effect of removal of associated proteins on the protease
resistance of ligand-bound AR was examined with an immuno-
adsorbed receptor. In vitro produced receptor was adsorbed to
an agarose matrix with an immobilized antibody that recog-
nizes the N terminus of the AR. Subsequently, the resin was
washed with salt, which was reported to remove most of the
associated proteins from glucocorticoid and progesterone recep-
tors (31–33). The direct demonstration of the release of the
major heat shock protein HSP90 from the in vitro produced AR
was not feasible, due to the low amount of AR in the reticulo-
cyte lysate and the relatively high nonspecific binding of
HSP90 to the affinity resin. In an experiment with a larger
amount of unlabeled androgen receptors, obtained from LNCaP
cells, it was shown that the interaction of HSP90 with an
immunopurified AR is disturbed upon a salt wash, whereas
ligand binding remained (dissociation of HSP90 shown in Fig.
3, lane 15–18). Strikingly, when the in vitro produced 35S-
labeled AR on the affinity matrix was liganded with an anti-
androgen, trypsinization now resulted in the formation of a
29-kDa fragment (Fig. 3, lane 13), a fragment with the same
size as formed with agonists (Fig. 3, lane 12). Trypsinization of
unliganded, and of androgen- or RU486-bound, immunoad-
sorbed AR showed results similar as seen with the non-immu-
noabsorbed receptor (compare Fig. 3, lanes 11, 12, and 14 with
Fig. 2A, lanes 7, 11, and 15). These results suggest that, after
removal of associated proteins, antiandrogens, except RU486,
are able to stabilize the same protease resisting conformation
as agonists.
Limited Trypsinization of Mutated Androgen Receptors—As
described in the section on transcription activation, hydroxy-
flutamide and cyproterone acetate could activate the mutant
receptor ARL, whereas ICI 176.334 and RU486 were antago-
FIG. 2. Limited trypsinization of androgen- and antiandrogen-
bound AR. A, in vitro produced [35S]AR was incubated for the indi-
cated time (min) at 25 °C in the presence of vehicle (2), R1881 (10 nM),
hydroxyflutamide (OH-F, 10 mM) or RU486 (1 mM) before limited tryptic
(100 mg/ml) digestion for 1 h at 0 °C. The trypsin-treated samples were
denatured and electrophoresed on a 12.5% acrylamide gel. Autoradiog-
raphy was performed overnight. B, in vitro produced [35S]AR was incu-
bated for 1 h at 25 °C in the presence of R1881 (lanes 16 and 17),
hydroxyflutamide (lanes 18 and 19), or RU486 (lanes 20 and 21) and
subjected to limited trypsinization (20 mg trypsin/ml, 15 min at 25 °C);
thereafter samples were either left on ice (2; lanes 16, 18, and 20) or
immunoprecipitated with the polyclonal antiserum SP066 (SP066;
lanes 17, 19, and 21).
FIG. 3. Effect of molybdate and removal of associated proteins
on limited trypsinization of AR. A, in vitro produced [35S]AR was
incubated (1 h at 25 °C) in the presence of vehicle (2), R1881 (10 nM),
hydroxyflutamide (OH-F; 10 mM), or RU486 (1 mM), with (1) or without
(2) molybdate (20 mM). Before limited trypsinization (20 mg trypsin/ml,
15 min at 25 °C), molybdate was added to 20 mM in all samples. B,
[35S]AR was immunoprecipitated with the antiserum SP197 and salt-
washed (0.5 M NaCl), before incubation with ligands as above. Limited
digestion was performed with trypsin (5 mg/ml, 15 min at 25 °C), and
samples were analyzed as described in the legend of Fig. 2. C, HSP90
interaction with the AR. AR in cytosol obtained from LNCaP cells was
immunoprecipitated with the antibody F39.4.1, washed without (2;
lane 16) or with (1; lane 18) NaCl (0.5 M), and after electrophoresis
visualized on a Western blot. Lanes 15 and 17 show nonspecific binding
of HSP90 to the affinity resin without antibody F39.4.1. AR and HSP90
were stained with the specific antibodies F39.4.1 and AC88,
respectively.
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nists also for ARL. Binding of hydroxyflutamide and cyprot-
erone acetate to ARL induced an increase of the resistance of a
29-kDa fragment to trypsinization, indicating that both anti-
androgens could induce a proteolysis resisting conformation of
the receptor normally only seen with androgen receptor ago-
nists (Fig. 4, result shown for R1881 and hydroxyflutamide:
lanes 3 and 4). For ICI 176.334 only a minor increase in inten-
sity of the 35-kDa fragment is seen, and no formation of a
29-kDa fragment (Fig. 4, lane 6). RU486 protected a fragment
of 25 kDa to trypsinization, similar as seen for the wild-type
receptor (Fig. 4, lane 5). So, it appears that the mutation in
ARL did not affect the conformational changes of ARL induced
by these last two antagonists.
Deletion of the last 12 amino acid residues of the ligand
binding domain of the AR completely abolished [3H]R1881
binding (22). In studies with the wild-type androgen receptor
described above, we observed protection by RU486 of a frag-
ment of the receptor lacking the C-terminal amino acids. To
study the effect of a deletion of 12 amino acid residues at the C
terminus in a limited proteolytic digestion assay, AR 1–898
was produced in vitro and incubated with different ligands.
Limited proteolytic digestion resulted for both agonists and
antagonists, except RU486, in a complete digestion of AR
1–898 into fragments not detectable after electrophoresis (Fig.
4, lanes 9 and 10), similar as observed in the absence of ligand
(Fig. 4, lane 8). The complete digestion of AR 1–898 indicates
the necessity of ligand binding for resistance against
trypsinization. RU486 protected a 25-kDa fragment of AR
1–898 against proteolytic degradation, indicating that the C-
terminal amino acids are not required for RU486 binding (Fig.
4, lane 11). The efficiency of protection of the 25-kDa fragment,
however, is lower in comparison with wild-type AR. The bind-
ing affinity of [3H]RU486 was determined by Scatchard plot
analysis (results not shown). The observed lower binding affin-
ity of RU486 for AR 1–898 (Kd 5.4 nM) as compared to AR (Kd
1.6 nM) may explain the lower efficiency of protection of AR
1–898 by RU486. The study with the mutant AR 1–898 pro-
vides additional evidence for a different mechanism of action of
the antagonist RU486.
Sucrose Density Gradient Centrifugation—The experiments
with molybdate-stabilized and salt-treated receptor complexes
provided indirect evidence for a process, in which a change in
proteolysis resisting conformation occurred simultaneously
with a change in interaction with other proteins. Additional
indications for such a process were obtained from the estima-
tion of sedimentation values of ligand-receptor complexes on
sucrose density gradients. In vitro produced AR was complexed
with [3H]R1881 or [3H]RU486, or labeled with [35S]methionine
and complexed with unlabeled ligands. Incubation was per-
formed at 0 °C or at 25 °C, to mimic the incubation conditions
as used for trypsinization of the receptor. AR liganded at 0 °C,
with either the androgen [3H]R1881 or the antiandrogen
[3H]RU486, sedimented as an 8 S complex (Fig. 5, A and B).
Incubation at 25 °C resulted in formation of a 5 S complex with
R1881 and a 4 S complex with RU486. Therefore, both ligands,
which induced a second conformational change of the AR at
25 °C as detected by limited trypsinization, also transformed
an initially present 8 S receptor complex into a smaller complex
on warming. Incubation of 35S-AR complexed with non-radio-
active R1881 showed similar 8 S and 4 S receptor forms as with
[3H]R1881-labeled receptor (compare Fig. 5, B and C). In con-
trast, only 8 S complexes were present after an incubation at
25 °C of the AR in the absence of ligand or in the presence of the
antagonists cyproterone acetate, hydroxyflutamide, ICI
176.334, and RU 23908 (Fig. 5, D and E).
The antagonists hydroxyflutamide and cyproterone acetate
could activate transcription with the mutant ARL and pro-
tected a 29-kDa fragment of ARL against trypsinization, indic-
ative for the release of associated proteins. The effect of binding
of these ligands to ARL on the sedimentation value of the
receptor complex was also studied. Indeed, both ligands partly
shifted the initial 8 S complex to a 5 S complex after an
incubation at 25 °C (Fig. 5F, result shown for hydroxyflut-
amide). A shift in sedimentation value of ARL from 8 S to 5 S
in the presence of agonists, or to 4 S in the presence of RU486,
was seen on warming, equivalent to the results obtained with
the wild-type AR. Unliganded and ICI 176.334-bound ARL
sedimented as an 8 S complex also at 25 °C, a result similar as
found for the wild-type AR (results not shown).
In summary, the sucrose gradient centrifugation studies
show that an 8 S receptor complex was present under condi-
tions when a 35-kDa fragment could be demonstrated by lim-
ited trypsinization. A 5 S complex correlated with a proteolysis
resisting fragment of 29 kDa, and was characteristic for the
receptor form able to induce transcription. Binding of RU486 to
the AR resulted in formation of a complex different from the
agonist-receptor complex in both proteolysis resisting confor-
mation and sedimentation characteristics (4 S) (results are
summarized in Fig. 6).
DISCUSSION
Proteolytic analysis has proven to be a powerful method to
analyze agonist- and antagonist-induced conformational
changes of progesterone (11, 12), estrogen (13), glucocorticoid
(11), androgen (10, 16, 17), and retinoic acid receptors (34). In
the present study, a detailed analysis of protease resisting
fragments permitted the identification of two conformational
changes after the binding of androgens. Immediately upon
binding of an agonist to the wild-type AR, the ligand binding
domain (amino acids 662–910) and part of the hinge region
(amino acids 612–662) resisted trypsinization (form 2 in Fig.
6), indicative for a more compact structure of the liganded
protein than in the absence of ligand. After this rapid initial
structural alteration, a second conformational change occurred
as detected with limited trypsinization, concomitantly with a
shift of a receptor complex sedimenting at 8 S to a complex
sedimenting at 5 S (form 3 in Fig. 6). In analogy to other steroid
hormone receptors (reviewed in Ref. 28), the high molecular
mass form of the AR presumably represents a complex of sev-
eral proteins, including the 90-kDa heat-shock protein (23, 35,
36). The second conformational change likely results in disso-
ciation of this complex and precedes the formation of a tran-
scriptionally active complex. The antiandrogens cyproterone
acetate and hydroxyflutamide, which are agonists for the mu-
tant ARL, induced in this mutant the two conformational
changes, and released associated proteins. Previous studies
with ARL already indicated that for the formation of the tran-
FIG. 4. Limited trypsinization of mutated androgen receptors.
Both in vitro produced ARL (A) and AR 1–898 (B) were incubated (1 h
at 25 °C) in the presence of vehicle (2), R1881 (10 nM), hydroxyflut-
amide (OH-F, 10 mM) or RU486 (1 mM), before limited trypsinization (20
mg/ml, 15 min at 25 °C). Lanes 1 and 6 are controls (C) without trypsin
added. In lane 11 the position of the 25-kDa fragment is indicated (,).
The band below 61 kDa is nonspecific.
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scriptionally active form the release of HSPs is essential (26). It
can be assumed that the single amino acid change in the ARL
made it possible for cyproterone acetate and hydroxyflutamide
to induce both the second conformational change and HSP
dissociation, which results in agonistic activity.
Two nonexclusive models have previously been postulated to
explain the mechanism of action of steroid receptor antago-
nists. In the first model, two types of antagonists are proposed
(37–39). Both types of compounds compete with agonists for
binding to the receptor, but they differ in their effect on sub-
sequent steps in the mechanism of receptor activation. The so
called “pure antagonists” have no partial agonistic activity,
probably due to decreased dimerization (38, 40), decreased
binding of the receptor complex to DNA (41–42), or increased
turnover (43). The other type of antagonists (“non-pure antag-
onists” with partial agonistic activity) provokes the transfor-
mation of the receptor to the DNA binding form but fails to
promote its transcriptional activity, probably through the in-
duction of an inappropriate conformation of the C-terminally
located transcription activation region (AF-2) (44, 45). The cell
and gene specific partial agonistic effects of some estrogen and
progesterone receptor antagonists have been explained by the
action of the ligand-independent transcription activation re-
gion (AF-1) (38, 41, 46). This division in two types of antago-
nists has been challenged. For the “pure antiestrogen” ICI
164.384 (40), DNA binding was observed in some studies (9,
47). For the antiprogestagen ZK 98299 the failure of the recep-
tor to interact with DNA (38) was subscribed to the lower
FIG. 5. Sucrose gradient centrifugation of androgen receptors. Sucrose density gradient (5–20%) centrifugation of radioactive labeled
receptor, incubated for 2 h at 0 °C (l) or 1 h at 25 °C (E). A and B, labeling of AR occurred with [3H]steroid. Excess of unbound [3H]steroid was
removed by dextran-coated charcoal; nonspecific binding was determined by incubation in the presence of 100-fold excess of unlabeled steroid for
2 h at 0 °C ( ). C-F, 35S-labeled receptor was incubated in the absence or presence of ligand as above, prior to sucrose density gradient
centrifugation. Panel F, results for mutant receptor ARL are shown. Fractions were subjected to electrophoresis, followed by autoradiography.
Autoradiograms were scanned to determine optical density (arbitrary unit). Aldolase (7.9 S), alkaline phosphatase (6.2 S), and hemoglobin (4.6 S)
were used as standards. OH-F, hydroxyflutamide.
FIG. 6. Different forms of the androgen receptor. Five different
forms of the androgen receptor can be detected with limited trypsiniza-
tion and sucrose density gradient centrifugation. Form 1 represents the
unoccupied receptor. Form 2 is obtained in the presence of either one of
the various antagonists, except RU486, and also after the initial bind-
ing of agonists at 4 °C. Upon incubation of the androgen receptor with
the agonist at 25 °C, Form 3 is found. Forms 4 and 5, derived of Forms
2 and 3, are found in the presence of RU486. Part of the domain
structure of the androgen receptor is shown schematically on top of the
figure.
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binding affinity of the ligand for the receptor (48) and could
be overcome by increasing the ligand concentration. However,
ZK 98299 could prevent the agonistic activity of the (“non-
pure”) antiprogestagen RU486 after stimulation of the cAMP
signaling pathways (49). A not yet well understood difference
in phosphorylation of the receptor could possibly play a role
(48, 50).
In a second model explaining the mechanism of antagonists,
described recently by O’Malley and collaborators (4, 5, 11), the
importance of a conformational change of the ligand binding
domain is emphasized. The model argues that agonists and
antagonists recognize distinct regions of the ligand binding
domain. Antagonists induce an incomplete conformational
change that results in dimerization and DNA binding, but
leave the C terminus of the ligand binding domain in a form
still available for protease (11) and antibody recognition (14,
15). As a result, a surface repressor function is not removed and
the receptor is not able to induce transcription.
We would propose to incorporate both models described
above in one scheme, and add an additional step that might be
inhibited by antagonists, to explain the results of our studies
with the antiandrogens cyproterone acetate, hydroxyflutamide,
ICI 176.334, and RU 23908 (Fig. 7). The key point of this model
is the step between a ligand-occupied complex of the receptor
and associated proteins, and a receptor that has a changed
conformation and has released these proteins. This step (step B
in Fig. 7) is partly or completely blocked by the antiandrogens
cyproterone acetate, hydroxyflutamide, ICI 176.334, and RU
23908. This step in the process of receptor activation has been
previously proposed as a step that is impaired by antagonists
(51–53), but recent observations of DNA-bound receptors occu-
pied with antagonists do not favor this step as critical for the
action of most antiprogestogens and antiestrogens (6). We like
to stress that more than one step may be involved in the
mechanism of antagonist action, and that a strict division of
antagonists in distinct categories might not be appropriate.
The pure antagonists of the estrogen and progesterone receptor
induce a partial conformational change, and might block the
process of receptor activation at step C (DNA-binding, dimer-
ization, and/or phosphorylation by nuclear kinases) in Fig. 7.
However, from our studies on antiandrogens, we have no new
arguments to support an absolute distinction between antago-
nists blocking either step C or step D (interaction with the
transcription initiation complex) in Fig. 7. RU486, when bound
to the androgen receptor, induced an inappropriate conforma-
tional change of the receptor, but also showed partial agonistic
properties apart from its antagonistic action. This might indi-
cate inhibition of step D in Fig. 7, and emphasized that anti-
androgenic activity may be exerted by different mechanisms.
Several data support the inhibition of step B (Fig. 7) in the
above described model for the action of the androgen receptor
antagonists cyproterone acetate, hydroxyflutamide, ICI
176.334, and RU 23908. Binding of these antiandrogens first
induced a rapid initial change within the AR, similar as seen in
the presence of agonists and indicative for a comparable initial
binding site on the receptor. However, in the presence of the
above mentioned antiandrogens no indication for the induction
of a second conformational change or release of associated
proteins in vitro could be detected. Furthermore, no support
was found for the involvement of the C terminus of the AR in
the mechanism of action of the four antiandrogens mentioned
above. Despite the presence of several protease degradation
sites, the C terminus was always present in the proteolysis
resisting fragment, obtained after limited proteolysis of these
antiandrogen-receptor complexes. In addition, the mutant AR
1–898, with a C-terminal deletion of 12 amino acids, does not
bind androgens (22) and could not induce a protease resisting
conformation in the presence of androgens and the four anti-
androgens. This suggests that the C terminus is involved in
binding of both androgens and the four antiandrogens, and
consequently that these antiandrogens must interfere with
another step in the process of receptor activation.
In conclusion, our data indicate that the antiandrogens
cyproterone acetate, hydroxyflutamide, ICI 176.334, and RU
23908 act at a different step in the mechanism of action of
steroid hormones than several antiprogestagens and antiestro-
gens. These antiandrogens do not induce or stabilize an inap-
propriate conformation of the C-terminal end of the receptor,
but act earlier and prevent a conformation change presumably
by stabilizing a complex with different associated proteins.
RU486 has a broad steroid specificity, and also binds to the
androgen receptor. This latter compound showed that antian-
drogenic activity might also be accomplished in a different way,
by induction of a non-functional conformation of the ligand
binding domain, similar as found for its effect on the proges-
terone receptor.
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